Compare Liberty Global Ltd Class C (LBTYK) vs Moderna, Inc. (MRNA) Price & Performance

LBTYK trades at $10.015, up 0.25% on the day, amid a bearish technical signal but strong analyst support. The stock shows mixed earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while the company navigates the Ziggo Group spin-off planned for 2027. Financially, it has a low P/S of 0.7 and P/B of 0.37, but negative net income and ROE highlight profitability challenges, offset by solid operating cash flow of $1.21 billion in 2025.

The outlook is cautiously optimistic, with the Ziggo Group listing in 2027 offering a potential catalyst, but persistent losses and competitive pressures pose risks. Analyst consensus is strongly bullish with 69% buy ratings, suggesting underlying value despite near-term headwinds.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.